Effects of KRAS mutation variants on tumor regression grade of rectal cancer received neoadjuvant therapy
10.12025/j.issn.1008-6358.2024.20240246
- VernacularTitle:KRAS基因突变亚型对直肠癌新辅助治疗后肿瘤退缩的影响
- Author:
Jiali LI
1
;
Chen XU
;
Xiaolei ZHANG
;
Yingyong HOU
Author Information
1. 复旦大学附属中山医院病理科,上海 200032
- Keywords:
rectal cancer;
neoadjuvant therapy;
tumor regression;
KRAS gene;
mutation subtype
- From:
Chinese Journal of Clinical Medicine
2024;31(3):389-393
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of KRAS mutation isoforms on tumor regression grade(TRG)of rectal cancer received neoadjuvant therapy.Methods The clinicopathologic data of patients with locally advanced and metastatic rectal cancer(stage Ⅲ-Ⅳ)who underwent radical tumor resection after neoadjuvant therapy were collected.The correlations between the mutated subtypes of KRAS and TRG as well as the clinicopathological features were analyzed.Results A total of 95 patients were enrolled,including 55 patients with poor tumor regression.The incidences of G12V mutation in exon 2 and A146 mutation in exon 4 of the KRAS gene were higher in the group with poor tumor regression than those in the significant tumor regression group(P＜0.05).In patients with G12D mutation of KRAS gene,the histological grade of tumor in poor tumor regression was higher than that in significant tumor regression group(P=0.027).In patients with poor tumor regression,the levels of CD8+,PD-1+T-lymphocyte infiltration were higher in G12D mutation subgroup than those in G12V mutation and G13D mutation subgroups(P＜0.05).Conclusions KRAS G12V mutation and A146 mutation suggest poor neoadjuvant therapy effect for rectal cancer;for patients with KRAS G12D mutation and poor tumor regression,the potential beneficiary for immunotherapy would be screened by detecting CD8+and PD-1+T-lymphocyte infiltration.
